This meta-analysis tells us that patients with active malignancies and severe aortic stenosis have a good evolution after transcatheter aortic valve replacement (TAVR), except for a higher rate of pacemaker implantation in the general population. These patients must not be limited to respite care only, at least as far as aortic stenosis is concerned. Short-term<a href="https://solaci.org/en/2020/05/26/malignancies-and-aortic-stenosis-is-tavr-warranted/" title="Read more" >...</a>
Despite the use of the different imaging approaches to calculating implantation depth, optimal depth is reached only 30% of the time. Multiple imaging does not offer a uniform perspective and therefore influence reporting. Basically, we do not have a clear idea of what constitutes optimal depth on a case by case basis and, what is<a href="https://solaci.org/en/2020/05/20/in-search-of-the-optimal-depth-for-self-expandable-valves/" title="Read more" >...</a>
Transcatheter aortic valve replacement (TAVR) seems to be safe in low-risk patients with bicuspid aortic valve stenosis. Their hospital length of stay was very short, with zero mortality, and zero disabling stroke. Subclinical leaflet thrombosis and device durability are still unknown. The United States Food and Drug Administration (FDA) approved TAVR for low-risk patients. However,<a href="https://solaci.org/en/2020/04/27/tavr-reaches-low-risk-patients-with-bicuspid-valves/" title="Read more" >...</a>
Technique advancements in left main coronary artery angioplasty have turned this procedure into a reasonable alternative to surgery, particularly in patients with a low or intermediate Syntax score and, obviously, those in whom surgery was contraindicated. Results can be credited to a refinement in technique, better drug-eluting stents, better patient selection, and frequent use of<a href="https://solaci.org/en/2020/04/15/ivus-in-left-main-coronary-artery-angioplasty-luxury-or-necessity/" title="Read more" >...</a>
Doing a balloon aortic valvuloplasty can be a good way to “buy” time before a transcatheter aortic valve replacement (TAVR), according to a registry to be published this week in J Am Coll Cardiol Intv. This study analyzed the database of a whole country to find out the incidence, predictors and outcomes of balloon aortic<a href="https://solaci.org/en/2020/04/13/aortic-valvuloplasty-as-a-bridge-to-tavr-are-we-wasting-our-time/" title="Read more" >...</a>
Direct implantation (without predilation) resulted non-inferior vs. the conventional strategy with prior balloon aortic valvuloplasty using the S3 prosthesis (even though this did not translate into a simplified procedure). In a few patients, the prosthesis was not able to cross the native valve, which resulted in device retrieval and subsequent valvuloplasty. According to these data,<a href="https://solaci.org/en/2020/04/07/predilation-in-tavr-definitive-data-for-easier-decision-making/" title="Read more" >...</a>
The initial results of this study presented “virtually” at the American College of Cardiology (ACC) 2020 Scientific Session suggest that patients with severe bicuspid aortic stenosis can be treated with self-expandable valve Evolut. This is a small study presenting its 30-day outcomes. There is still a long way to go. The rate of all-cause mortality<a href="https://solaci.org/en/2020/04/02/virtual-acc-2020-first-results-of-evolut-in-low-risk-bicuspid-valves/" title="Read more" >...</a>
Transcatheter aortic valve replacement with the self-expandable valves has shown optimal clinical and electrocardiographic results in patients with small annuli. These supra-annular prosthetic valves seem somewhat better than the intra-annular balloon expandable. TAVR in general has better functional results in terms of patient/prosthesis mismatch. This seems especially true for patients with a small annulus. The<a href="https://solaci.org/en/2020/03/20/tavr-in-small-annuli-is-there-a-better-valve/" title="Read more" >...</a>
The Interventional Cardiology Association and the Cardiac Beat Association from the Spanish Society of Cardiology have released a document stating all the available information on the COVID-19 outbreak for interventionists to tackle this health crisis to the best of their ability. ” Abstract “During March 2020, the SARS-CoV-2 virus has spread throughout Europe, with special<a href="https://solaci.org/en/2020/03/16/cath-lab-management-protocol-for-the-covid-19-outbreak/" title="Read more" >...</a>